Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 122 clinical trials
None
Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)

AIO-YMO/TRK-0416 (DURATION) is a open-label, treatment stratified and randomized phase II study of Durvalumab, frail or elderly patients with metastatic non-squamous NSCLC with no targetable molecular alterations (EGFRwt; ALKtransl-) and not amenable to cisplatinum-based standard-combination chemotherapy but eligible for at-least mono-chemotherapy with gemcitabine or vinorelbine.

stage iv non-small cell lung cancer
carboplatin/paclitaxel
solid tumour
systemic therapy
paclitaxel
  • 107 views
  • 29 Jan, 2021
  • 41 locations
None
A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.

The purpose of this study is to assess whether dacomitinib after osimertinib is effective in participants with metastatic EGR-mutant lung cancers.

lung cancer
osimertinib
stage iv non-small cell lung cancer
erlotinib
gefitinib
  • 5 views
  • 05 Sep, 2021
  • 8 locations
None
Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 3 Bone-only Metastases

metastasis in sarcoma and colorectal cancers with liver or lung metastasis. We chose to focus on bone metastasis because of their high incidence, their impact on the patient's quality of life and autonomy

pulmonary metastasis
lung cancer
primary tumor
solid neoplasm
stereotactic radiation
  • 34 views
  • 05 Mar, 2021
  • 16 locations
None
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Soft Tissue or Bone Sarcoma Metastatic to the Lungs

This phase I/II trial studies the side effects of pulmonary suffusion in controlling minimal residual disease in patients with soft tissue or bone sarcoma that has spread to the lungs. Pulmonary suffusion is a minimally invasive delivery of chemotherapeutic agents like cisplatin to lung tissues. Drugs used in chemotherapy, such …

sarcoma
measurable disease
dyspnea
antineoplastic
isolated chemotherapeutic lung perfusion
  • 0 views
  • 26 Nov, 2021
  • 1 location
None
Lung Perfusion PET / CT Using Ga68-MAA for Preservation of Lung Function During Stereotactic Pulmonary Radiation Therapy

This is a prospective study evaluating the feasibility of treatment planning integrating lung perfusion PET/CT using Ga68-MAA to preserve functional lung areas during stereotactic body radiation therapy (SBRT).

  • 0 views
  • 06 Aug, 2021
  • 1 location
None
Surveillance AFter Extremity Tumor surgerY

Following treatment for a primary extremity sarcoma, patients remain at risk for the development of local and systemic disease recurrence. Metastasis (distant recurrence) to the lung is the most frequent single location of disease recurrence in sarcoma patients, occurring in almost half of all patients. Therefore, careful post-operative surveillance is …

cancer chemotherapy
metastasis
sarcoma
sarcoma of the extremity
chest ct
  • 0 views
  • 19 Mar, 2021
  • 11 locations
None
A Clinical Study of Intravenous T3011 Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

This is a Phase 1/2a open label study to evaluate the safety and preliminary efficacy of intravenous T3011 given alone and in combination with intravenous pembrolizumab in participants with advanced or metastatic solid tumors.

measurable disease
pembrolizumab
metastasis
  • 0 views
  • 02 Sep, 2021
  • 4 locations
None
Indo-cyanine Green (ICG) in Paediatric Oncology MIS

Indo-cyanine green (ICG) is a dye that has been used for a variety of adult and paediatric uses since 1956. Over the past few years, near infrared (NIRF) technology has been developed which allow is use as a fluorescence agent during surgery. It has been used increasingly in the field …

cancer
metastasis
  • 0 views
  • 19 Aug, 2021
  • 1 location
None
Study on SBRT for Inoperable Lung and Liver Oligometastases From Breast Cancer

Investigators designed a phase II study to evaluate safety and efficacy of lung and liver stereotactic radiation therapy (SRT) in oligometastatic breast cancer patients unsuitable for surgery, using VMAT RapidArc approach.

cancer
endocrine therapy
stereotactic radiation
hormone therapy
vmat
  • 10 views
  • 25 Mar, 2021
  • 1 location
None
Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation

This is a Phase II, non-randomized, open-label study to assess the efficacy, safety, and tolerability of dabrafenib and trametinib in stage IV disease to subjects with BRAF V600E mutant advanced non-small cell lung cancer. Subjects will receive dabrafenib 150 mg bid and trametinib 2 mg once daily in combination therapy …

lung cancer
primary cancer
trametinib
measurable disease
dabrafenib
  • 13 views
  • 22 Jan, 2021
  • 1 location